sign up for retatrutide trial New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Phase III trial shows up

PMC 3541499

If the FDA finalizes its April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B Bulks List, large-scale 503B compounding of those medications would no longer be legally permissible

That's according to the National Institute of Diabetes and Digestive and Kidney Diseases

This "traffic jam" leads to glutathione shortages, making your body vulnerable to everyday stressors like infections, toxins, or even stress itself

For example, ET patients often have subtle cerebellar ataxia manifested by difficulty in tandem gait [187], and a subset of ET patients will eventually develop frank ataxia [188]